Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NCT06933056
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Platelet Function and Reactivity Tests
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Michigan
- Last updated on ClinicalTrials.gov
- September 15, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- University of Michigan · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.